The EIF3M Knockout HeLa Polyclonal Cells consist of a CRISPR/Cas9-edited HeLa cell population harboring targeted disruptions of the EIF3M gene. This polyclonal knockout model provides a genetically diverse pool of cells with loss-of-function alleles, avoiding the clonal artifacts that can arise in single-cell-derived lines. The product enables robust investigation of EIF3M function in translation initiation and oncogenic signaling.
HeLa cells are a well-characterized HPV18-positive cervical adenocarcinoma line widely used as a cancer model. These epithelial cells display rapid proliferation, aneuploidy, and constitutive activation of mTOR and MYC pathways, making them suitable for studying cap-dependent translation control. The HPV18 E6 and E7 oncoproteins disable key tumor suppressors, creating a permissive background for examining gene functions relevant to multiple malignancies.
EIF3M is a non-core subunit of the eIF3 translation initiation complex that enhances eIF3?CeIF4G interaction, promoting cap-dependent ribosome recruitment on mRNAs with structured 5?? UTRs. It operates downstream of mTOR and MYC and is critical for selective translation of growth-promoting mRNAs encoding cyclin D1 and c-MYC. Core eIF3 subunits (eIF3A, eIF3B, eIF3C) and the eIF4G scaffold participate in complex assembly; mTOR activates the pathway via S6K1 and 4E-BP1, which releases eIF4E to initiate cap binding. EIF3M loss thus perturbs translation initiation downstream of these regulators.
In HeLa cells, EIF3M knockout provides a powerful system to dissect cap-dependent translation initiation and its contribution to cancer cell proliferation. Disruption of EIF3M is expected to weaken the eIF3?CeIF4G scaffold, diminishing synthesis of proteins that drive cell cycle progression. This model is pertinent to hepatocellular carcinoma, breast cancer, and colorectal cancer research, where EIF3M overexpression has been observed. The polyclonal population captures a spectrum of editing outcomes, enabling population-level analyses of translation phenotypes without clonal bias.
Typical applications include Western blotting and RT-qPCR for target depletion validation, polysome profiling and dual luciferase assays to measure cap-dependent translation, co-immunoprecipitation to assess eIF3 complex integrity, and functional readouts such as proliferation, cell cycle analysis by flow cytometry, and apoptosis assays. These tools support studies in cancer biology, translation regulation, drug target validation, and functional genomics. For further details, please contact Ascent Research.
